![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Elbasvir/Grazoprevir in Cirrhotic Patients With HCV Infection
|
|
|
Reported by Jules Levin
25th Asian Pacific Association for the Study of the Liver; February 20-24, 2016; Tokyo, Japan.
Paul Kwo1; Ira Jacobson2; Eric Lawitz3; Christophe Hezode4; Cheng-Yuan Peng5; Anita Howe6; Peggy Hwang6; Janice Wahl6; Michael Robertson6; Eliav Barr6; Barbara Haber6
1Indiana University School of Medicine, Indianapolis, IN, USA;
2Mount Sinai Beth Israel, New York, NY, USA; 3Texas Liver
Institute, University of Texas Health Science Center,
San Antonio, TX, USA; 4Henri Mondor Hospital, Creteil, France;
5China Medical University Hospital, Taichung, Taiwan;
6Merck & Co., Inc., Kenilworth, NJ, USA
![APASL1](../images/022216/022216-10/APASL1.gif)
![APASL2](../images/022216/022216-10/APASL2.gif)
![APASL3](../images/022216/022216-10/APASL3.gif)
![APASL4](../images/022216/022216-10/APASL4.gif)
![APASL5](../images/022216/022216-10/APASL5.gif)
![APASL6](../images/022216/022216-10/APASL6.gif)
![APASL7](../images/022216/022216-10/APASL7.gif)
![APASL8](../images/022216/022216-10/APASL8.gif)
![APASL9](../images/022216/022216-10/APASL9.gif)
![APASL10](../images/022216/022216-10/APASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|